Enter your search terms:

Investor Relations

Aquestive Therapeutics Corporate Profile

Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. The Company has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, as well as orally administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. The most advanced product candidates developed to treat varying CNS diseases include Libervant and AQST-117 (Riluzole). SympazanTM (clobazam), oral film for the adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS), received FDA approval. As the leader in developing and delivering drugs via its PharmFilm® technology, the Company also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the Company with its partners has a portfolio of development-stage products and commercialized products, such as Suboxone, the market leader for the treatment of opioid dependence.

Copyright West LLC. Minimum 15 minutes delayed.

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds